ethyl 2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-8-nonenoate | 342898-83-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-8-nonenoate
• 英文别名: ethyl 2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)non-8-enoate
• CAS: 342898-83-3
• 化学式: C₁₇H₂₃F₉O₂
• 分子量: 430.354
• InChiKey: HSUHSTZCIBYYHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  28
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  ethyl 2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-8-nonenoate 在 palladium on activated charcoal sodium hydroxide 、 Grubbs catalyst first generation 、 氢气 、 三溴化硼 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 10-[3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl]-2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)decanoic acid
  参考文献：
  名称：

  Newly discovered orally active pure antiestrogens

  摘要：

  In order to develop orally active pure antiestrogens, we incorporated the carboxy-containing side chains into the 7 alpha-position of the steroid scaffold and found that 17-keto derivative CH4893237 (12b) functioned as a pure antiestrogen with its oral activity much superior to clinically used pure antiestrogen, ICI182,780. Results from the pharmacokinetic evaluation indicated that the potent antiestrogen activity at oral dosing in mice attributed to both improved absorption from the intestinal wall and metabolic stability in liver. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.047
• 作为产物：
  描述：

  diethyl 2-(6-heptenyl)-2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)malonate 在 lithium chloride 作用下， 以 水 、 二甲基亚砜 为溶剂， 以89%的产率得到ethyl 2-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-8-nonenoate
  参考文献：
  名称：

  3-methyl-chroman and -thiochroman derivatives

  摘要：

  本发明提供了具有以下一般式（1）的化合物： 其中R1代表氢原子等；R2代表C3-C3全卤代烷基等；R3和R4各自独立地代表氢原子等；X代表氧原子或硫原子；m代表2至14的整数；n代表0至8的整数；或该化合物的对映体、水合物或药用可接受的盐。一般式（1）的化合物在药用上具有抗雌激素活性，具有优势。

  公开号：

  US06552069B1

文献信息

• Compounds with hydroxycarbonyl-halogenoalkyl side chain
  申请人：——

  公开号：US20030114524A1

  公开（公告）日：2003-06-19

  The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): 1 in which R 1 represents a hydrogen atom, etc., R 2 represents a C 1 -C 7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

  本发明提供了一种化合物，包括一个与所述基团化学键合的基团和一个含有口服后活性较低的化合物或其母体骨架的基团的部分，其中所述基团具有以下一般式（1）：其中R1代表氢原子，等，R2代表C1-C7卤代烷基基团，等，m代表2至14的整数，n代表2至7的整数，或该化合物的对映体，或该化合物的水合物或药用可接受盐，或其对映体。上述化合物在药用上具有优势，因为一般式（1）的基团使得类似抗雌激素的化合物附着在化合物的母体骨架上口服后显示出显著增加的活性。
• Compounds with hydroxycarbonyl-halogenoalkyl side chains
  申请人：Jo JaeChon

  公开号：US20050192449A1

  公开（公告）日：2005-09-01

  The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R 1 represents a hydrogen atom, etc., R 2 represents a C 1 -C 7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

  本发明提供了一种化合物，该化合物由一个基团和与该基团化学键合的基团组成，其中该基团包含一种在口服后具有低活性的化合物或其母体支架，而该基团具有以下一般式（1）：其中R1代表氢原子等，R2代表C1-C7卤代烷基等，m表示2到14的整数，n表示2到7的整数，或该化合物的对映体，或其水合物或药学上可接受的盐。上述化合物在药学上的使用中具有优点，因为一般式（1）的基团使得诸如抗雌激素类化合物等连接到化合物的母体支架上后，在口服后能够显著增加其活性。
• 3-ethyl-, 3-propyl- or 3-butyl-chroman and thiochroman derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US06552068B1

  公开（公告）日：2003-04-22

  A compound having the following general formula (1): in which R1 represents an ethyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C5 perhalogenoalkyl group, etc.; each of R4 and R5 independently represents a hydrogen atom, etc.; X represents an oxygen atom or a sulfur atom; m represents an integer of 2 to 14; and n represents an integer of 2 to 7; or an enantiomer of the compound, or a hydrate or a pharmaceutically acceptable salt of the compound or its enantiomer is advantageous in pharmaceutical use because of its anti-estrogenic activity.

  具有以下通式（1）的化合物： 其中，R1代表乙基基团等；R2代表氢原子等；R3代表C1-C5卤代烷基团等；R4和R5各自独立地代表氢原子等；X代表氧原子或硫原子；m表示2到14的整数；n表示2到7的整数；或该化合物的对映体或水合物或药学上可接受的盐，在药物使用中具有抗雌激素活性的优点。
• COMPOUND HAVING HYDROXYCARBONYL-HALOGENOALKYL SIDE CHAIN
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1241158A1

  公开（公告）日：2002-09-18

  The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1represents a hydrogen atom, etc., R2represents a C1-C7 halogenoalkyl group, etc., mrepresents an integer of 2 to 14, and nrepresents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

  本发明提供了一种由一个分子和一个与所述分子化学键合的基团组成的化合物，其中所述分子包含口服后活性较低的化合物或其母体支架，所述基团具有以下通式(1)： 其中 R1 代表氢原子等 R2 代表 C1-C7 卤代烷基等、 m 代表 2 至 14 的整数，以及 n 代表 2 至 7 的整数、 或化合物的对映体，或化合物或其对映体的水合物或药学上可接受的盐。上述化合物在医药用途方面具有优势，因为通式（1）的基团可以使诸如抗雌激素类的化合物在口服后附着在化合物的母支架上，显示出显著增加的活性。
• 3-METHYL-CHROMAN AND -THIOCHROMAN DERIVATIVES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1241166A1

  公开（公告）日：2002-09-18

  The present invention provides a compound having the following general formula (1): in which    R1 represents a hydrogen atom, etc.;    R2 represents a C3-C5 perhalogenoalkyl group, etc.;    each of R3 and R4 independently represents a hydrogen atom, etc.;    X represents an oxygen atom or a sulfur atom;    m represents an integer of 2 to 14; and    n represents an integer of 0 to 8; or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or its enantiomers. The compound of general formula (1) is advantageous in pharmaceutical use because of its anti-estrogenic activity.

  本发明提供了具有以下通式(1)的化合物： 其中 R1 代表氢原子等 R2 代表 C3-C5 全卤代烷基等； R3 和 R4 各自独立地代表氢原子等； X 代表氧原子或硫原子； m 代表 2 至 14 的整数；以及 n 代表 0 至 8 的整数； 或该化合物的对映体，或该化合物或其对映体的水合物或药学上可接受的盐。通式（1）化合物具有抗雌激素活性，因此在医药用途中具有优势。